Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs
Spyros Kolovos(IQVIA (United Kingdom)), Rafael Pinedo‐Villanueva(Nuffield Orthopaedic Centre), Daniel Prieto‐Alhambra(Nuffield Orthopaedic Centre), Mark T. Drayson(Institute of Immunology), Matthew Streetly(King's College - North Carolina), Bhuvan Kishore(National Health Service), M K Javaid(Nuffield Orthopaedic Centre), Kwee Yong(CRUK Lung Cancer Centre of Excellence), Andrew Chantry(University of Sheffield), Karthik Ramasamy(Oxford University Hospitals NHS Trust), Stella Bowcock(King's College Hospital), Cyrus Cooper(University Hospital Southampton NHS Foundation Trust), Guido Nador(Oxford University Hospitals NHS Trust), John Ashcroft(Leeds Teaching Hospitals NHS Trust), Neil Rabin(University College London)
Cited by 20
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe
|European Heart Journal|2021|1.7k
Common genetic determinants of vitamin D insufficiency: a genome-wide association study
|The Lancet|2010|1.5k
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women
|Osteoporosis International|2007|1.2k
Association of Cardiometabolic Multimorbidity With Mortality
|JAMA|2015|1.2k